IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
-3.03%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$705M
AUM Growth
+$705M
(-7.5%)
Cap. Flow
-$3.36M
Cap. Flow
% of AUM
-0.48%
Top 10 Holdings %
Top 10 Hldgs %
36.96%
Holding
95
New
21
Increased
24
Reduced
14
Closed
29
Top Buys
| 1 |
Tenet Healthcare
THC
|
$20.3M |
| 2 |
Amgen
AMGN
|
$17.5M |
| 3 |
Medtronic
MDT
|
$17.2M |
| 4 |
Becton Dickinson
BDX
|
$16.8M |
| 5 |
DexCom
DXCM
|
$16.3M |
Top Sells
| 1 |
Cigna
CI
|
$34.3M |
| 2 |
Zimmer Biomet
ZBH
|
$25.8M |
| 3 |
Centene
CNC
|
$13.5M |
| 4 |
AbbVie
ABBV
|
$13.5M |
| 5 |
Schrodinger
SDGR
|
$13.2M |
Sector Composition
| 1 | Healthcare | 99.61% |
| 2 | Consumer Discretionary | 0.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Pfizer
PFE
$141B
| $4.98M | 0.69% |
+150,000
| New | +$4.98M |
|
52
Cooper Companies
COO
$13.3B
| $4.77M | 0.66% |
60,000
-148,000
| -71% | -$11.8M |
|
53
Replimune Group
REPL
$460M
| $4.28M | 0.59% |
250,000
-195,000
| -44% | -$3.34M |
|
|
LBPH
54
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $4.23M | 0.59% |
760,000
+162,000
| +27% | +$901K |
|
55
Envista
NVST
$3.37B
| $4.18M | 0.58% |
150,000
| – | – |
|
56
Zoetis
ZTS
$67.6B
| $3.48M | 0.48% |
+20,000
| New | +$3.48M |
|
|
WW
57
DELISTED
WW International
WW
| $2.77M | 0.38% |
+250,000
| New | +$2.77M |
|
58
Tandem Diabetes Care
TNDM
$834M
| $2.7M | 0.37% |
+130,000
| New | +$2.7M |
|
|
BPMC
59
DELISTED
Blueprint Medicines
BPMC
| $2.51M | 0.35% |
+50,000
| New | +$2.51M |
|
60
HCA Healthcare
HCA
$95.4B
| $2.46M | 0.34% |
10,000
-30,000
| -75% | -$7.38M |
|
|
SILK
61
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $2.25M | 0.31% |
+150,000
| New | +$2.25M |
|
|
RVNC
62
DELISTED
Revance Therapeutics, Inc.
RVNC
| $1.15M | 0.16% |
100,000
-150,000
| -60% | -$1.72M |
|
63
Novo Nordisk
NVO
$252B
| – | – |
0
| – | – |
|
64
Penumbra
PEN
$10.5B
| – | – |
-30,000
| Closed | -$10.3M |
|
65
Prothena Corp
PRTA
$452M
| – | – |
-52,000
| Closed | -$3.55M |
|
66
Privia Health
PRVA
$2.85B
| – | – |
-200,000
| Closed | -$5.22M |
|
67
PTC Therapeutics
PTCT
$4.41B
| – | – |
-174,000
| Closed | -$7.08M |
|
68
Protagonist Therapeutics
PTGX
$3.62B
| – | – |
-75,000
| Closed | -$2.07M |
|
69
uniQure
QURE
$954M
| – | – |
0
| – | – |
|
|
SAGE
70
DELISTED
Sage Therapeutics
SAGE
| – | – |
-80,000
| Closed | -$3.76M |
|
|
71
AbbVie
ABBV
$374B
| – | – |
-100,000
| Closed | -$13.5M |
|
72
Allogene Therapeutics
ALLO
$249M
| – | – |
-412,000
| Closed | -$2.05M |
|
73
Alnylam Pharmaceuticals
ALNY
$58.6B
| – | – |
-52,000
| Closed | -$9.88M |
|
74
Apellis Pharmaceuticals
APLS
$3.51B
| – | – |
-72,000
| Closed | -$6.56M |
|
75
BioMarin Pharmaceuticals
BMRN
$11.3B
| – | – |
-50,000
| Closed | -$4.33M |
|